Ascendis Pharma Oncology Division A/S
CVR 41034076 · Public limited company (A/S) · Active · Medium risk
Ascendis Pharma Oncology Division A/S is a Public limited company (A/S), founded on , based in Hellerup. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 6 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -501.6m and a net result of DKK -110.1m. CEO: Jan Møller Mikkelsen.
Bankruptcy risk for Ascendis Pharma Oncology Division A/S
1.0 × the average (1.41%) · higher risk than 77% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 41034076
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (6 years)
- Address
- Tuborg Boulevard 12
2900 Hellerup - Municipality
- Gentofte
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 900k
- Auditor
- DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 6 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | – |
| Current ratio | 0% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 224 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -85.2m | DKK -92.5m | DKK -140.1m |
| Net profit | DKK -110.1m | DKK -106.4m | DKK -144.1m |
| Equity | DKK -501.6m | DKK -391.5m | DKK -285.1m |
| Total assets | DKK 0 | DKK 99k | DKK 457k |
| Cash | DKK 0 | DKK 99k | – |
| Short-term debt | DKK 14.2m | DKK 14k | – |
| Avg. employees | 0 | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Auditor's report on audited financial statements · Deloitte Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 91 | ||
| 1 Jan 2024 – 31 Dec 2024 | 126 | ||
| 1 Jan 2023 – 31 Dec 2023 | 94 | ||
| 1 Jan 2022 – 31 Dec 2022 | 83 | ||
| 1 Jan 2021 – 31 Dec 2021 | 129 | ||
| 13 Dec 2019 – 31 Dec 2020 | 88 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Jan Møller Mikkelsen | Current | |
| Board | Michael Wolff Jensen | Current | |
| Board | Jan Møller Mikkelsen | Current | |
| Board | Anni Lotte Kirstine Pedersen | Current | |
| Owner (100%) | ASCENDIS PHARMA A/S | Current | |
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Founder | ASCENDIS PHARMA A/S | Current |
The CEOs' other companies
Jan Møller Mikkelsen – 15 other companies
- 7TM A/S Opløst
- ASCENDIS PHARMA A/S Active
- ASCENDIS PHARMA BONE DISEASES A/S Active
- ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S Active
- Ascendis Pharma Endocrinology Division A/S Active
- Ascendis Pharma Europe A/S Active
- Ascendis Pharma Growth Disorders A/S Active
- Ascendis Pharma Nordics A/S Opløst
- CADENZA PARTNERS ApS Active
- Cadenza Partners 2 ApS Active
- HYSCITE DISCOVERY A/S Compulsorily dissolved
- MAXYGEN ApS Opløst
- NEURONICON ApS Opløst
- NUEVOLUTION A/S Active
- PROFOUND INVEST A/S Opløst
Address history (0 moves)
| Tuborg Boulevard 12, 2900 Hellerup |
Other companies at the same address
- AFV-SELSKABET AF 8. JULI 2009 ApS Bankrupt
- AFVIKLINGSSELSKABET AF DEN 8. MAJ 2006 ApS Bankrupt
- AFVIKLINGSSELSKABET AF DEN 8. MAJ 2006 HOLDINGS ApS Bankrupt
- ANPARTSSELSKABET 11. MAJ 2006 Bankrupt
- ANPARTSSELSKABET AF 3.2.2004 Bankrupt
- All about IT Europe ApS Bankrupt
- ApS AF 9. NOVEMBER 2006 GENTOFTE Bankrupt
- B18 DANMARK ApS Bankrupt
- BROBY OVERDREV, EJENDOMSANPARTSSELSKAB Bankrupt
- BogM IT ApS Bankrupt
- Boligfonden LIAB ApS Bankrupt
- Brdr. Daugaard ApS Bankrupt
- Bygge Mester ApS Bankrupt
- CAMANN ApS Bankrupt
- CARCARE-EUROPE ApS Bankrupt
- CCE CAPITAL S.M.B.A. Bankrupt
- CID ApS Bankrupt
- CONSULTING LEAGUE ADVISORY ApS Bankrupt
- Clear Quality Holding IVS Bankrupt
- DK Accounting ApS Bankrupt
- DK Legal Advice ApS Bankrupt
- DKL 13 ApS Bankrupt
- DKL 15 ApS Bankrupt
- DKL 16 ApS Bankrupt
- DKL 17 ApS Bankrupt
Similar companies in Gentofte
- Lica Pharma ApS Hellerup
- SKN computation ApS Gentofte
- WinQure Medicine ApS Klampenborg
- Illum Biotech ApS Charlottenlund
- Novo Nordisk Clinical Innovation Centre A/S Gentofte
- Bollværk ApS Hellerup
- Epitopea ApS Klampenborg
- Spectoceutics ApS Gentofte
- CENEXUM Technologies ApS Gentofte
- Protein Frontiers ApS Gentofte
- ClinOption ApS Dyssegård
- Merian Life Sciences ApS Hellerup
Questions and answers about Ascendis Pharma Oncology Division A/S
Has Ascendis Pharma Oncology Division A/S gone bankrupt?
No, Ascendis Pharma Oncology Division A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Ascendis Pharma Oncology Division A/S?
Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.
Who is the CEO of Ascendis Pharma Oncology Division A/S?
Jan Møller Mikkelsen is the CEO of Ascendis Pharma Oncology Division A/S.
Who is the auditor of Ascendis Pharma Oncology Division A/S?
Ascendis Pharma Oncology Division A/S most recently used DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was Ascendis Pharma Oncology Division A/S founded?
Ascendis Pharma Oncology Division A/S was founded on 13 December 2019.
What is the equity of Ascendis Pharma Oncology Division A/S?
Equity was DKK -501.6m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.